脓毒症患者首次医嘱后抗菌药物供给延迟与死亡率
该观察性队列和病例对照研究纳入4,429例连续就诊于急诊科的新发脓毒症或脓毒性休克成人患者,以首次抗菌药物医嘱至首次给药时间(抗菌药物前置时间)为暴露指标,以0-1小时为金标准对照。50%患者抗菌药物前置时间超过1.3小时。校正后,前置时间1-2小时、3-6小时和>12小时的28天死亡比值比分别为1.28(95%CI 1.07-1.54;p=0.007)、1.57(95%CI 1.26-1.95;p<0.001)和1.85(95%CI 1.29-2.65;p=0.001),呈现剂量-反应效应。作者认为抗菌药物前置时间是客观、可测量且可干预的流程指标。
要点
- 50%脓毒症患者从首次抗菌药物医嘱到给药的前置时间超过1.3小时。
- 前置时间1-2小时者28天死亡校正OR为1.28(95%CI 1.07-1.54;p=0.007)。
- 前置时间3-6小时者28天死亡校正OR为1.57(95%CI 1.26-1.95;p<0.001)。
- 前置时间>12小时者28天死亡校正OR为1.85(95%CI 1.29-2.65;p=0.001)。
- 前置时间2-3小时和6-12小时的校正OR未达统计学显著。
适用人群与场景
- 急诊科就诊的新发脓毒症或脓毒性休克成人患者。
研究设计与关键结果
- 观察性队列和病例对照研究,纳入4,429例连续急诊科新发脓毒症成人患者,以0-1小时抗菌药物前置时间为金标准对照。
- 50%患者抗菌药物前置时间超过1.3小时。
- 前置时间1-2小时:28天死亡校正OR 1.28(95%CI 1.07-1.54;p=0.007)。
- 前置时间2-3小时:校正OR 1.07(95%CI 0.85-1.36;p=0.6),未达统计学显著。
- 前置时间3-6小时:校正OR 1.57(95%CI 1.26-1.95;p<0.001)。
- 前置时间6-12小时:校正OR 1.36(95%CI 0.99-1.86;p=0.06),未达统计学显著。
- 前置时间>12小时:校正OR 1.85(95%CI 1.29-2.65;p=0.001)。
证据类型、等级与局限
- 证据类型:观察性队列和病例对照研究。
- 局限:原文报告回顾性研究固有的偏倚适用于本研究。
对床旁实践的改变
- 作者认为抗菌药物前置时间是客观、可测量且可干预的流程指标,不同于难以捕捉的脓毒症起病和识别。
- 作者认为首次抗菌药物执行延迟常见且有害,已知生物学机制支持这些发现,并显示剂量-反应效应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: There is mounting evidence that delays in appropriate antimicrobial administration are responsible for preventable deaths in patients with sepsis. Herein, we examine the association between potentially modifiable antimicrobial administration delays, measured by the time from the first order to the first administration (antimicrobial lead time), and death among people who present with new onset of sepsis.
DESIGN: Observational cohort and case-control study.
SETTING: The emergency department of an academic, tertiary referral center during a 3.5-year period.
PATIENTS: Adult patients with new onset of sepsis or septic shock.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We enrolled 4,429 consecutive patients who presented to the emergency department with a new diagnosis of sepsis. We defined 0-1 hour as the gold standard antimicrobial lead time for comparison. Fifty percent of patients had an antimicrobial lead time of more than 1.3 hours. For an antimicrobial lead time of 1-2 hours, the adjusted odds ratio of death at 28 days was 1.28 (95% CI, 1.07-1.54; p = 0.007); for an antimicrobial lead time of 2-3 hours was 1.07 (95% CI, 0.85-1.36; p = 0.6); for an antimicrobial lead time of 3-6 hours was 1.57 (95% CI, 1.26-1.95; p < 0.001); for an antimicrobial lead time of 6-12 hours was 1.36 (95% CI, 0.99-1.86; p = 0.06); and for an antimicrobial lead time of more than 12 hours was 1.85 (95% CI, 1.29-2.65; p = 0.001).
CONCLUSIONS: Delays in the first antimicrobial execution, after the initial clinician assessment and first antimicrobial order, are frequent and detrimental. Biases inherent to the retrospective nature of the study apply. Known biologic mechanisms support these findings, which also demonstrate a dose-response effect. In contrast to the elusive nature of sepsis onset and sepsis onset recognition, antimicrobial lead time is an objective, measurable, and modifiable process.
参考来源
- Kashiouris MG, Zemore Z, Kimball Z, et al. Supply Chain Delays in Antimicrobial Administration After the Initial Clinician Order and Mortality in Patients With Sepsis. Crit Care Med. 2019. PMID: 31343474. doi:10.1097/CCM.0000000000003921
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。